Evidence map›Paper›PMID 26883191›Full record

ArticleOncotarget2016

CCL-34, a synthetic toll-like receptor 4 activator, modulates differentiation and maturation of myeloid dendritic cells.

Shu-Ling Fu, Chun-Cheng Lin, Ming-Ling Hsu, Sheng-Hung Liu, Yu-Chuen Huang, Yu-Jen Chen

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Serine-/Cysteine-Based spJournal of medicinal chemistry · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Shu-Ling FuInstitute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan.
Chun-Cheng LinDepartment of Chemistry, National Tsing Hua University, Hsinchu, Taiwan.
Ming-Ling HsuDepartment of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan.
Sheng-Hung LiuInstitute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan.
Yu-Chuen HuangSchool of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
Yu-Jen ChenInstitute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan.
Mackay Memorial Hospital · TWChina Medical University · TWNational Tsing Hua University · TWNational Yang Ming Chiao Tung University · TWNational Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CCL-34, a synthetic α-galactosylceramide analog, has been reported as an activator of toll-like receptor 4 (TLR4) in macrophages. TLR4 is highly expressed in dendritic cell (DC) and several TLR4 agonists are known to trigger DC maturation. We herein evaluated the effect of CCL-34 on DC maturation. Human CD14+ monocyte-derived immature DC were treated with CCL-34, its inactive structural analog CCL-44, or LPS to assess the DC maturation. CCL-34 induced DC maturation according to their characteristically dendrite-forming morphology, CD83 expression and IL-12p70 production. The allostimulatory activity of DC on proliferation of naive CD4+CD45+RA+ T cells and their secretion of interferon-γ was increased by CCL-34. Phagocytosis, an important function of immature DC, was reduced after CCL-34 treatment. All these effects related to DC maturation were evidently induced by positive control LPS but not by CCL-44 treatment. TLR4 neutralization impaired human DC maturation triggered by CCL-34. The induction of IL-12, a hallmark of DC maturation, by CCL-34 and LPS was only evident in TLR4-competent C3H/HeN, but not in TLR4-defective C3H/HeJ mice. CCL-34 could further elicit the antigen presentation capability in mice inoculated with doxorubicin-treated colorectal cancer cells. In summary, CCL-34 triggers DC maturation via a TLR4-dependent manner, which supports its potential application as an immunostimulator.

Indexed as

AnimalsCell DifferentiationCell ProliferationDendritic CellsGlycolipidsHumansMiceMice, Inbred BALB CMice, Inbred C3HMyeloid CellsSerineSignal TransductionCCL 34GlycolipidsSerineCCL-34dendritic celldifferentiationmaturationTLR4

Identifiers

PMID26883191
PMCPMC4905502
OpenAlexW2280248634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.